5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Participants will get treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.Achievable new methods for the analysis and treatment of AML. (A) The identification of super en